ResearcherOsaka International Cancer InstituteActive in the last 2 years
Yoji Kukita
Matched on ORCID iD 0000-0003-3523-2816; OpenAlex author ID A5060371374. Sources: OpenAlex.
Their work
- Papers
- 5
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 21
2018: 1 paper · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: none · 2026: 2 papers
Papers 5
- Clinical significance of non-invasive in vitro drug sensitivity profiling using pancreatic cancer organoids derived from saline flushes collected during routin… Co-author DOI 10.1007/s12094-025-04111-9↗
- Differential Diagnosis of Solitary Pulmonary Nodules in Postoperative Pancreatic Cancer Patients Using KRAS Gene Mutation Analysis. Co-author DOI 10.1245/s10434-025-18659-x↗
- Utility of Comprehensive Genomic Profiling Tests for Patients with Incurable Pancreatic Cancer in Clinical Practice. Co-author DOI 10.3390/cancers15030970↗
- Clinical Utility of Pancreatic Cancer Circulating Tumor DNA in Predicting Disease Progression, Prognosis, and Response to Chemotherapy. Co-author DOI 10.1097/mpa.0000000000001652↗
- Selective identification of somatic mutations in pancreatic cancer cells through a combination of next-generation sequencing of plasma DNA using molecular barc… Co-author DOI 10.1371/journal.pone.0192611↗
Closest collaborators
The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Ryoji Takada · 4 shared papers, 2018–2026 · strength 0.59
- Paper Clinical significance of non-invasive in vitro drug sensitivity profiling using pancreatic cancer organoids derived fro… DOI 10.1007/s12094-025-04111-9↗
- Paper Utility of Comprehensive Genomic Profiling Tests for Patients with Incurable Pancreatic Cancer in Clinical Practice. DOI 10.3390/cancers15030970↗
- Paper Clinical Utility of Pancreatic Cancer Circulating Tumor DNA in Predicting Disease Progression, Prognosis, and Response … DOI 10.1097/mpa.0000000000001652↗
- Kazuyoshi Ohkawa · 4 shared papers, 2018–2026 · strength 0.59
- Paper Clinical significance of non-invasive in vitro drug sensitivity profiling using pancreatic cancer organoids derived fro… DOI 10.1007/s12094-025-04111-9↗
- Paper Utility of Comprehensive Genomic Profiling Tests for Patients with Incurable Pancreatic Cancer in Clinical Practice. DOI 10.3390/cancers15030970↗
- Paper Clinical Utility of Pancreatic Cancer Circulating Tumor DNA in Predicting Disease Progression, Prognosis, and Response … DOI 10.1097/mpa.0000000000001652↗
- Kenji Ikezawa · 3 shared papers, 2020–2026 · strength 0.49
- Paper Clinical significance of non-invasive in vitro drug sensitivity profiling using pancreatic cancer organoids derived fro… DOI 10.1007/s12094-025-04111-9↗
- Paper Utility of Comprehensive Genomic Profiling Tests for Patients with Incurable Pancreatic Cancer in Clinical Practice. DOI 10.3390/cancers15030970↗
- Paper Clinical Utility of Pancreatic Cancer Circulating Tumor DNA in Predicting Disease Progression, Prognosis, and Response … DOI 10.1097/mpa.0000000000001652↗
- Yugo Kai · 2 shared papers, 2023–2026 · strength 0.39
- Paper Clinical significance of non-invasive in vitro drug sensitivity profiling using pancreatic cancer organoids derived fro… DOI 10.1007/s12094-025-04111-9↗
- Paper Utility of Comprehensive Genomic Profiling Tests for Patients with Incurable Pancreatic Cancer in Clinical Practice. DOI 10.3390/cancers15030970↗
- Makiko Urabe · 2 shared papers, 2023–2026 · strength 0.39
- Paper Clinical significance of non-invasive in vitro drug sensitivity profiling using pancreatic cancer organoids derived fro… DOI 10.1007/s12094-025-04111-9↗
- Paper Utility of Comprehensive Genomic Profiling Tests for Patients with Incurable Pancreatic Cancer in Clinical Practice. DOI 10.3390/cancers15030970↗
- Hirofumi Akita · 1 shared paper, 2026 · strength 0.27
- Ryu Kanzaki · 1 shared paper, 2026 · strength 0.27
- Kunihito Gotoh · 1 shared paper, 2026 · strength 0.27
- Jiro Okami · 1 shared paper, 2026 · strength 0.27
- Shinichiro Hasegawa · 1 shared paper, 2026 · strength 0.25
- Hisataka Ogawa · 1 shared paper, 2026 · strength 0.25
- Hidenori Takahashi · 1 shared paper, 2026 · strength 0.25
- Tomoya Ekawa · 1 shared paper, 2026 · strength 0.25
- Shigenori Nagata · 1 shared paper, 2026 · strength 0.25
- Hideaki Tahara · 1 shared paper, 2026 · strength 0.25
- Takuo Yamai · 2 shared papers, 2020–2023 · strength 0.24
- Paper Utility of Comprehensive Genomic Profiling Tests for Patients with Incurable Pancreatic Cancer in Clinical Practice. DOI 10.3390/cancers15030970↗
- Paper Clinical Utility of Pancreatic Cancer Circulating Tumor DNA in Predicting Disease Progression, Prognosis, and Response … DOI 10.1097/mpa.0000000000001652↗
- Kikuya Kato · 2 shared papers, 2018–2020 · strength 0.20
- Paper Clinical Utility of Pancreatic Cancer Circulating Tumor DNA in Predicting Disease Progression, Prognosis, and Response … DOI 10.1097/mpa.0000000000001652↗
- Paper Selective identification of somatic mutations in pancreatic cancer cells through a combination of next-generation seque… DOI 10.1371/journal.pone.0192611↗
- Nobuyasu Fukutake · 1 shared paper, 2020 · strength 0.10
- Reiko Ashida · 1 shared paper, 2020 · strength 0.10
- Kazuhiro Katayama · 1 shared paper, 2020 · strength 0.10
- Kazuhiro Katayama · 1 shared paper, 2018 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.